300 related articles for article (PubMed ID: 22994268)
1. Topical Ranibizumab inhibits inflammatory corneal hem- and lymphangiogenesis.
Bucher F; Parthasarathy A; Bergua A; Onderka J; Regenfuss B; Cursiefen C; Bock F
Acta Ophthalmol; 2014 Mar; 92(2):143-8. PubMed ID: 22994268
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.
Bock F; Onderka J; Dietrich T; Bachmann B; Kruse FE; Paschke M; Zahn G; Cursiefen C
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2545-52. PubMed ID: 17525183
[TBL] [Abstract][Full Text] [Related]
3. Serum eyedrops antagonize the anti(lymph)angiogenic effects of bevacizumab in vitro and in vivo.
Hos D; Koch KR; Bucher F; Bock F; Cursiefen C; Heindl LM
Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6133-42. PubMed ID: 23970469
[TBL] [Abstract][Full Text] [Related]
4. Blockade of the VEGF isoforms in inflammatory corneal hemangiogenesis and lymphangiogenesis.
Lipp M; Bucher F; Parthasarathy A; Hos D; Onderka J; Cursiefen C; Bock F
Graefes Arch Clin Exp Ophthalmol; 2014 Jun; 252(6):943-9. PubMed ID: 24728466
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation.
Hos D; Bock F; Dietrich T; Onderka J; Kruse FE; Thierauch KH; Cursiefen C
Invest Ophthalmol Vis Sci; 2008 May; 49(5):1836-42. PubMed ID: 18436817
[TBL] [Abstract][Full Text] [Related]
6. The effect of podoplanin inhibition on lymphangiogenesis under pathological conditions.
Maruyama Y; Maruyama K; Kato Y; Kajiya K; Moritoh S; Yamamoto K; Matsumoto Y; Sawane M; Kerjaschki D; Nakazawa T; Kinoshita S
Invest Ophthalmol Vis Sci; 2014 Jul; 55(8):4813-22. PubMed ID: 24985477
[TBL] [Abstract][Full Text] [Related]
7. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation.
Bachmann BO; Bock F; Wiegand SJ; Maruyama K; Dana MR; Kruse FE; Luetjen-Drecoll E; Cursiefen C
Arch Ophthalmol; 2008 Jan; 126(1):71-7. PubMed ID: 18195221
[TBL] [Abstract][Full Text] [Related]
8. Short- and long-term corneal vascular effects of tafluprost eye drops.
Hos D; Koch KR; Bock F; Grajewski RS; Dietlein TS; Cursiefen C; Heindl LM
Graefes Arch Clin Exp Ophthalmol; 2013 Aug; 251(8):1919-27. PubMed ID: 23624591
[TBL] [Abstract][Full Text] [Related]
9. Intracellular thiol redox status regulates lymphangiogenesis and dictates corneal limbal graft survival.
Fukumoto A; Maruyama K; Walsh T; Kajiya K; Hamuro J; D'Amore PA; Kinoshita S
Invest Ophthalmol Vis Sci; 2010 May; 51(5):2450-8. PubMed ID: 20042658
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Lymphangiogenesis and Hemangiogenesis in Corneal Inflammation by Subconjunctival Prox1 siRNA Injection in Rats.
Rho CR; Choi JS; Seo M; Lee SK; Joo CK
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5871-9. PubMed ID: 26348636
[TBL] [Abstract][Full Text] [Related]
11. Angiopoietin-2 promotes inflammatory lymphangiogenesis and its effect can be blocked by the specific inhibitor L1-10.
Yan ZX; Jiang ZH; Liu NF
Am J Physiol Heart Circ Physiol; 2012 Jan; 302(1):H215-23. PubMed ID: 22058148
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib inhibits inflammatory corneal lymphangiogenesis.
Detry B; Blacher S; Erpicum C; Paupert J; Maertens L; Maillard C; Munaut C; Sounni NE; Lambert V; Foidart JM; Rakic JM; Cataldo D; Noël A
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3082-93. PubMed ID: 23580490
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib.
Lin T; Gong L
Drug Des Devel Ther; 2017; 11():1147-1158. PubMed ID: 28435226
[TBL] [Abstract][Full Text] [Related]
14. Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids.
Hos D; Saban DR; Bock F; Regenfuss B; Onderka J; Masli S; Cursiefen C
Arch Ophthalmol; 2011 Apr; 129(4):445-52. PubMed ID: 21482870
[TBL] [Abstract][Full Text] [Related]
15. Blockade of insulin receptor substrate-1 inhibits corneal lymphangiogenesis.
Hos D; Regenfuss B; Bock F; Onderka J; Cursiefen C
Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5778-85. PubMed ID: 21666240
[TBL] [Abstract][Full Text] [Related]
16. Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin.
Cursiefen C; Schlötzer-Schrehardt U; Küchle M; Sorokin L; Breiteneder-Geleff S; Alitalo K; Jackson D
Invest Ophthalmol Vis Sci; 2002 Jul; 43(7):2127-35. PubMed ID: 12091407
[TBL] [Abstract][Full Text] [Related]
17. Identification of Novel Endogenous Anti(lymph)angiogenic Factors in the Aqueous Humor.
Bock F; Onderka J; Braun G; Schneider AC; Hos D; Bi Y; Bachmann BO; Cursiefen C
Invest Ophthalmol Vis Sci; 2016 Dec; 57(15):6554-6560. PubMed ID: 27918829
[TBL] [Abstract][Full Text] [Related]
18. The maintenance of lymphatic vessels in the cornea is dependent on the presence of macrophages.
Maruyama K; Nakazawa T; Cursiefen C; Maruyama Y; Van Rooijen N; D'Amore PA; Kinoshita S
Invest Ophthalmol Vis Sci; 2012 May; 53(6):3145-53. PubMed ID: 22511631
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival.
Cursiefen C; Cao J; Chen L; Liu Y; Maruyama K; Jackson D; Kruse FE; Wiegand SJ; Dana MR; Streilein JW
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2666-73. PubMed ID: 15277490
[TBL] [Abstract][Full Text] [Related]
20. Corneal Collagen Cross-Linking With Riboflavin and UVA Regulates Hemangiogenesis and Lymphangiogenesis in Rats.
Zhu Y; Li L; Reinach PS; Li Y; Ge C; Qu J; Chen W
Invest Ophthalmol Vis Sci; 2018 Jul; 59(8):3702-3712. PubMed ID: 30029257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
